Alimera

Alimera Sciences, Inc. Our lead product is ILUVIEN, now approved for marketing in the U.S. and 15 European countries for the treatment of diabetic macular edema.

(NASDAQ: ALIM) (“Alimera”), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.